Detecting Antibodies Secreted by Trapped Cells Using Extraordinary Optical Transmission

• Published in: IEEE sensors journal 2011-11, Vol.11 (11), p.2732-2739
• Main Authors: Romanuik, Sean F., Grist, S. M., Gray, B. L., Hohertz, D., Kavanagh, K. L., Gulzar, N., Scott, J. K., Nirwan, R., Hui, C., Brolo, A. G., Gordon, R.
• Format: Article
• Language: English
• Subjects: Antibodies; Arrays; Binding; Biomedical optical imaging; Cell trap; Charge carrier processes; Exposure; extraordinary optical transmission (EOT); Gold; immunobiosensor; Media; Nanomaterials; Nanostructure; Optical sensors; Optical surface waves; Silver; surface plasmon resonance (SPR)
• ISSN: 1530-437X; 1558-1748
• DOI: 10.1109/JSEN.2011.2158643

Isolation of monoclonal (M-) antibodies (Abs) from Ab-secreting cells (ASCs) is impeded by difficulties in identifying the minority of ASCs secreting Ab(s) of interest. We present a novel label-free system that traps ASCs into biocompatible microwells and detects the binding of secreted Ab(s), to a surface-immobilized antigen (Ag), as induced shifts in the extraordinary optical transmission (EOT) spectra through milled nanohole arrays. In this paper, a biotinylated target Ag (Bio-HA and Bio-2F5) is exposed to varying known MAb concentrations (17/9 and 2F5). The mean EOT shift in response to MAb concentration is similar in shape to specific MAb-Ag binding as seen in an ELISA. In another experiment, hybridoma cells secreting 17/9 MAb are trapped in wells inset into poly(dimethyl siloxane) (PDMS) (5-20 cells/trap), to which the nanohole arrays of Bio-HA "Sample" and Bio-2F5 "Ag Control" slides are aligned. Simultaneously, a Bio-HA "Media Control" slide is exposed to MAb-free media. The mean "Sample" shift (3.2 ±0.1 nm) is distinguished from the mean "Ag Control" shift (1.2 ±0.4 nm), but indistinguishable from the mean "Media Control" shift (3.6 ±0.3 nm). We have made significant progress in detecting Ab(s) secreted from trapped ASCs. With further development, our device could identify ASCs of interest rapidly, streamlining therapeutic MAb discovery.